About werewolf therapeutics inc - HOWL
Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.
HOWL At a Glance
Werewolf Therapeutics, Inc.
200 Talcott Avenue
Watertown, Massachusetts 02472
| Phone | 1-617-952-0555 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -60,822,000.00 | |
| Sector | Health Technology | Employees | 39 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
HOWL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.241 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.174 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 3.666 |
HOWL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,559,538.462 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
HOWL Liquidity
| Current Ratio | 1.621 |
| Quick Ratio | 1.621 |
| Cash Ratio | 1.578 |
HOWL Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -61.159 |
| Return on Equity | -123.88 |
| Return on Total Capital | -97.353 |
| Return on Invested Capital | -86.023 |
HOWL Capital Structure
| Total Debt to Total Equity | 151.869 |
| Total Debt to Total Capital | 60.297 |
| Total Debt to Total Assets | 54.284 |
| Long-Term Debt to Equity | 30.978 |
| Long-Term Debt to Total Capital | 12.299 |